Healing · compound · checked 2026-10-09

ARA-290 (Cibinetide)

ARA-290 (Cibinetide) is listed here as a compound. Erythropoietin-derived peptide engineered to target the innate repair receptor without ordinary erythropoietic activity. Status was checked 2026-10-09. This card reports cited facts. It does not tell you to use ARA-290 (Cibinetide) or how much to take.

Open the ARA-290 (Cibinetide) calculator How the math works

Last checked Oct 9, 2026 by PepBear. Not medical advice.

FDA product: not established
Compounding: not established
Research: investigational
Sport: unknown

What is ARA-290 (Cibinetide)?

Other names in the library: ARA290, cibinetide, ARA-290 10mg, ARA-290 — 16mg / Premium, ARA-290 — 8mg / Premium, ARA-290. Evidence describes the named substance, not a quality certification or equivalence assessment of commercial stock. Listed sizes: 8 mg, 10 mg, 16 mg. A seller title is a listing. It does not prove the vial matches a paper.

Erythropoietin-derived peptide engineered to target the innate repair receptor without ordinary erythropoietic activity.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Compounding

not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.

Research

investigational. 22 adults with sarcoidosis-associated small-fiber neuropathy in a blinded pilot trial.

Sport

unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.

What the cited papers actually measured

We mark the cited papers as C for 22 adults with sarcoidosis-associated small-fiber neuropathy in a blinded pilot trial. and Neuropathy symptom scores improved relative to placebo in this small study.. Small, short exploratory trial. It does not establish general injury recovery or commercial-vial equivalence. Neuropathy symptom scores improved relative to placebo in this small study. Small, short exploratory trial. It does not establish general injury recovery or commercial-vial equivalence. Risks on the record: Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.

We mark the cited papers as C. That is our label for how strong those papers are. It does not say the compound works.

human-trial

Neuropathy symptom scores improved relative to placebo in this small study.

22 adults with sarcoidosis-associated small-fiber neuropathy in a blinded pilot trial. Small, short exploratory trial. It does not establish general injury recovery or commercial-vial equivalence.

How long it lasts, how you store it, listed sizes

The catalog does not record a single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.

Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

U-100 math for listed ARA-290 (Cibinetide) sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial	1 mL liquid	2 mL liquid	3 mL liquid
8 mg	80	40	26.7
10 mg	100	50	33.3
16 mg	160	80	53.3

Risks and mix-ups already on the record

Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.

People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.

Sources

ARA-290 primary study · PMID 23168581 · checked 2026-10-09

Questions people ask

Is ARA-290 (Cibinetide) FDA-approved?

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Does PepBear pick an amount of ARA-290 (Cibinetide)?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.